Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00418171 · ClinicalTrials.gov registry record · Phase 4
Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 18,239
- Enrollment target
NCT00418171 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 18,239 participants.
The verdict
NCT00418171, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 18,239 participants
- Enrollment target
Study Summary
The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.
Interventions
- DRUG Olanzapine
- DRUG Ziprasidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,239 participants |
| Start Date | 2002-02 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00418171
The ClinicalTrials.gov registry entry for NCT00418171 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 18,239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT00418171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00418171 about?
NCT00418171 is a clinical study titled "Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)". The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.
What is the current status of trial NCT00418171?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 18,239 participants. The study started on 2002-02. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00418171?
The interventions under investigation include: Olanzapine (DRUG), Ziprasidone (DRUG).
Who is sponsoring clinical trial NCT00418171?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.